On 9 July 2025, CPE took part in the high-level webinar, “Unlocking the Untapped Potential of Comprehensive Genomic Profiling (CGP): Improving Patient Access and Outcomes”, hosted by the European Coalition for Genomic Profiling (ECGP). This timely discussion brought together experts and stakeholders from across Europe to explore how CGP can transform cancer care and what is needed to make this innovation more accessible to patients.
Our CEO, Antonella Cardone, delivered Recommendation #1 from ECGP Policy Report, focusing on the urgent need to improve awareness and understanding of CGP’s value.
“Ensuring equitable access to comprehensive genomic profiling is crucial for the advancement of precision medicine,” Antonella noted. “These diagnostics enable precise and timely identification of cancer types, allowing for tailored treatment plans that significantly improve patient outcomes.”
CGP offers a detailed molecular profile of tumours, guiding more effective, personalised treatment—especially for complex cancers like NSCLC, CUP, and breast cancer brain metastases. Studies show it significantly improves survival. However, access to CGP remains uneven across Europe. Availability doesn’t guarantee use, and many patients are never offered this vital diagnostic.
Antonella focused on three key priorities:
- Engagement with policymakers to communicate the clinical and economic value of CGP versus limited hotspot panels.
- Awareness campaigns for the public and patients to understand the availability and benefits of CGP.
- Education initiatives to help healthcare professionals interpret CGP reports and integrate them into treatment planning.
She also stressed the need for equitable implementation frameworks, including:
- Clear reimbursement and funding pathways for CGP, especially in high-evidence indications like NSCLC and CUP.
- Inclusion of CGP in national cancer care guidelines and support for Molecular Tumour Boards (MTBs).
- Cross-border data collection standards to strengthen clinical evidence and enable fair comparisons across Europe.
At CPE, we believe innovation must be matched by inclusion. That’s why we’re working closely with partners like ECGP to ensure every patient, regardless of geography or income, has access to high-quality diagnostics like CGP.

